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Abstract
Bacterial sequencing will become increasingly adopted in routine microbiology laboratories. Here, we report the findings of a 
technical evaluation of almost 800 clinical methicillin- resistant Staphylococcus aureus (MRSA) isolates, in which we sought to 
define key quality metrics to support MRSA sequencing in clinical practice. We evaluated the accuracy of mapping to a generic 
reference versus clonal complex (CC)- specific mapping, which is more computationally challenging. Focusing on isolates that 
were genetically related (<50 single nucleotide polymorphisms (SNPs)) and belonged to prevalent sequence types, concordance 
between these methods was 99.5 %. We use MRSA MPROS0386 to control for base calling accuracy by the sequencer, and used 
multiple repeat sequences of the control to define a permitted range of SNPs different to the mapping reference for this control 
(equating to 3 standard deviations from the mean). Repeat sequences of the control were also used to demonstrate that SNP 
calling was most accurate across differing coverage depths (above 35×, the lowest depth in our study) when the depth required 
to call a SNP as present was at least 4−8×. Using 786 MRSA sequences, we defined a robust measure for mec gene detection to 
reduce false- positives arising from contamination, which was no greater than 2 standard deviations below the average depth 
of coverage across the genome. Sequencing from bacteria harvested from clinical plates runs an increased risk of contamina-
tion with the same or different species, and we defined a cut- off of 30 heterozygous sites >50 bp apart to identify same- species 
contamination for MRSA. These metrics were combined into a quality- control (QC) flowchart to determine whether sequence 
runs and individual clinical isolates passed QC, which could be adapted by future automated analysis systems to enable rapid 
hands- off sequence analysis by clinical laboratories.
DATA SummARy
Sequence data generated during this study have been depos-
ited in the European Nucleotide Archive under the accession 
numbers listed in Table S2 (available in the online version of 
this article) (https://www. ebi. ac. uk/ ena).
InTRoDuCTIon
Research evidence for the practical utility of MRSA sequencing 
as an adjunct to infection control practice supports its intro-
duction into routine use. This includes the demonstration that 
sequencing is superior to other typing methods in discrimi-
nating between isolates of the same lineage [1–4], and that the 
combination of standard outbreak investigation and MRSA 
sequencing is superior to standard outbreak investigation 
alone [5]. Sequencing has been shown to exclude outbreaks 
in instances where patient clusters have occurred by chance 
[6], which could prevent unnecessary use of infection control 
resources. Furthermore, proactive use of MRSA sequencing 
has been proposed as part of a redesign in infection control 
practice [7], replacing the reactive use of typing as a late 
adjunct during established outbreak investigations. Support 
for this ‘Sequence First’ approach comes from a prospective 
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study of genomic MRSA surveillance over 12 months at a 
clinical microbiology laboratory, in which 2282 MRSA from 
1465 people were sequenced [5]. An integrated genomic and 
epidemiological analysis identified 173 separate transmission 
clusters containing between 2 and 44 cases and involving 
598 people that were not detected by conventional infection 
control approaches. Economic cost- effectiveness studies for 
proactive MRSA sequencing are lacking in the published 
literature but are on- going.
There has been considerable debate about whether pathogen 
sequencing should be performed in a centralized facility or 
distributed throughout the network of hospital- based diag-
nostic laboratories. However, the pace at which sequencing 
instruments are being developed for clinical use means that 
sequencing will become increasingly feasible in any setting 
provided that robust methods are available to support high- 
quality real- time sequencing, combined with the availability of 
fully automated tools that undertake relatedness comparisons 
and provide interpretation guidelines for use of this informa-
tion to healthcare workers without informatics expertise. This 
would support the rapid use of data to direct and optimize 
MRSA outbreak investigations. Progress has been made to 
describe the sequencing of MRSA within a 24 h time window 
(from the start of DNA extraction to sequence data genera-
tion) [8], which includes sequencing of colony picks directly 
from primary clinical culture plates [9]. Furthermore, a pilot 
evaluation of a commercial fully automated interpretation 
tool indicates that genetic relatedness can be generated within 
90 s per isolate [10].
Here, we report the findings of a technical evaluation of almost 
800 MRSA isolates that set out to define several key metrics 
that could support the analysis of MRSA sequence data in 
clinical practice. This includes the selection of mapping refer-
ence for relatedness determination using core- genome SNPs, 
the sequencing depth required to call a SNP, and defining 
cut- offs for the detection of mec genes and same- species 
contamination. These culminated in a quality- control (QC) 
metric flowchart to guide future adopters.
mETHoDS
Study setting, patients and sample identification
The study was conducted at the Clinical Microbiology and 
Public Health Laboratory at the Cambridge University 
Hospitals NHS Foundation Trust (CUH), UK, under ethical 
approval from the National Research Ethics Service (ref: 
11/EE/0499) and the Cambridge University Hospitals NHS 
Foundation Trust Research and Development Department 
(ref: A092428). Consecutive patients with samples that were 
MRSA positive were identified between 24 January and 1 
November 2018 using the hospital IT system [EPIC EMR 
(Hyperspace 2014; Epic Systems Corporation)]. One MRSA 
isolate from each patient (generally the first available) was 
sought for sequencing, together with all isolates cultured from 
blood cultures. In the first 3 months of the study (24 January 
to 3 April), this was achieved by isolate retrieval from the 
frozen archive to provide look- back data for the subsequent 
6- month prospective collection. Of the 147 cases identified 
with MRSA- positive samples in the first 3 months, 124 (84 %) 
patients had a stored MRSA isolate. Thereafter through to the 
end of the study, MRSA- positive cultures were retrieved in 
real- time from the clinical laboratory by the research team. 
Samples were flagged by laboratory staff and the culture 
plate retrieved on the same day, where possible. A total of 
772 patients were identified as having MRSA- positive samples 
during this second period, of which 673 patients (87 %) had a 
clinical culture retrieved from which MRSA was obtained and 
sequenced. After de- duplication of cases presenting in the first 
and second periods, a total of 789 isolates from 784 patients 
were processed for sequencing. Samples were renumbered 
with an anonymous study code upon entry into the study.
microbiology
Freezer archive samples were plated onto Columbia Blood 
Agar (CBA) using a 1 µl loop and incubated overnight at 
37 °C in air. A single colony was selected for sequencing, and 
a 10 µl loopful was stored at −80 °C in Microbank vials (Pro- 
lab Diagnostics). Plates that appeared contaminated were 
re- subbed onto CBA and incubated at 37 °C overnight prior 
to sequencing and re- storage. For prospectively obtained 
clinical samples, putative S. aureus was confirmed using the 
Staph Latex kit (Pro- lab Diagnostics). A single 2–3 mm colony 
was picked from clinical culture plates using a 1 µl loop and 
inoculated onto CBA and incubated overnight at 37 °C in air. 
Where colonies were smaller than 2 mm, several colonies 
were picked. Where bacterial growth was confluent (growth 
covering the majority or all of the agar plate), a 1 µl loopful 
was taken. If there were several positive plates for one clinical 
sample, the plate with the least visible background contamina-
tion was selected. As with the freezer archive, a single colony 
Impact Statement
Bacterial whole- genome sequencing is a highly discrimi-
natory technique that could be a powerful adjunct for 
infection control teams. This allows isolates (patients) to 
be identified as being part of an outbreak, enabling early 
action to prevent further dissemination. As importantly, 
isolates (patients) can be shown not to be linked with 
a suspected outbreak, preventing unnecessary infec-
tion control actions. Methicillin- resistant Staphylococcus 
aureus (MRSA) is a major cause of hospital infections 
and causes outbreaks both in hospitals and the commu-
nity. Whole- genome sequencing of MRSA can now be 
performed within 24 h, and tools are under development 
to rapidly analyse the resulting data without the need for 
expert input, but quality- control (QC) metrics are required 
for this tool to be used in clinical practice. In this study 
we defined a number of QC metrics to support MRSA 
sequencing in clinical practice, culminating in a QC flow-
chart that could be adopted or adapted by future users.
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was selected for sequencing, and a 10 µl loopful was stored at 
−80 °C in Microbank vials.
Sequencing and data analysis
Clinical MRSA isolates were sequenced in batches of 21 
isolates plus three controls (described below). DNA extrac-
tion was performed using the QIAgen QIAamp DNA Mini 
extraction kit with the protocol amendments described 
previously [8]. Library preparation was performed using the 
Illumina Nextera DNA Flex kit with the protocol amend-
ments described previously [8]. Isolates were sequenced on 
the Illumina MiniSeq with a run time of 13 h using the high 
output 150 cycle MiniSeq cartridge and the Generate Fastq 
workflow. Data were saved to an external hard drive. Species 
identification was performed using Kraken version 1 (https:// 
ccb. jhu. edu/ software/ kraken/) with the miniKraken data-
base (https:// ccb. jhu. edu/ software/ kraken/ dl/ minikraken_ 
20171019_ 8GB. tgz). Multilocus sequence type (ST) was 
identified using Ariba (https:// github. com/ sanger- pathogens/ 
ariba/ wiki/ MLST- calling- with_ ARIBA). Clonal complexes 
were determined based on assignments reported previously 
[5] or based on the allelic profile, allowing up to two alleles 
different to the reference ST. The presence of mecA (acces-
sion number HE681097, position 2790560 : 2792566), mecB 
(accession number AP009486, position 25 508–27 532) or 
mecC (accession number FR821779, position 35 681–37 678) 
was identified using Ariba (https:// github. com/ sanger- patho-
gens/ ariba). Fastq files were mapped to clonal- complex (CC) 
specific references using smalt (https://www. sanger. ac. uk/ 
science/ tools/ smalt- 0), as described previously [8], for all 
isolates that were assigned to a ST that contained more than 
ten clinical isolates. CC- specific references were CC1 MW2 
(accession number BA000033), CC5 N315 (accession number 
BA000018), CC8 USA300 (accession number CP000255), 
CC22 EMRSA15 (accession number HE681097), CC30 
MRSA252 (accession number BX571856), CC45 CA347 
(accession number CP006044) and CC59 M013 (accession 
number CP003166). In addition, all isolates were mapped to 
the CC22 EMRSA15 mapping reference. Variant calling and 
generation of the consensus fasta files were performed using 
Samtools and bcftools. Mobile genetic elements were removed 
from the alignment using the files available at http:// figshare. 
com/ authors/ Francesc_ Coll/ 5727779 and the script available 
in Github (https:// github. com/ sanger- pathogens/ remove_ 
blocks_ from_ aln. py). SNPs were identified using the script 
available in Github (https:// github. com/ sanger- pathogens/ 
snp_ sites). Pairwise differences in SNPs between isolate pairs 
was determined using the script available at https:// github. 
com/ simonrharris/ pairwise_ difference_ count. Heterozy-
gous SNPs (hetSNPs) were evaluated based on mapping to 
the CC22 reference and were identified as SNPs with <90 % 
support for a single base. The number of hetSNPs at least 
50 bp apart was determined using the script available at 
Github (https:// github. com/ kumarnaren/ mecA- HetSites- 
calculator), which required at least one read to be mapped in 
either orientation. The average coverage across the mapping 
reference, the standard deviation in coverage, and the depth 
of coverage for the mec gene of each isolate was determined 
using the same script. We downloaded genome sequence data 
for MRSA MPROS0386 generated previously over nine inde-
pendent sequencing runs [8] from the European Nucleotide 
Archive, which were used for the analysis of variation in SNPs 
in the positive control.
Contamination experiment
Detection of contamination with the same species was 
determined through a deliberate contamination experiment. 
MPROS1839 and MPROS2264 (both ST22s) were spiked 
with 0, 0.01, 0.1, 1, 10 and 20% concentration of DNA from 
MPROS0386 (ST22, ~100 SNPs from MPROS1839 and 
MPROS2264) and the resulting DNA combination sequenced 
as above.
QC metrics
Each sequencing run contained 21 clinical MRSA isolates and 
three controls [positive control (MRSA MPROS0386), nega-
tive control (Escherichia coli NCTC12241) and a no- template 
control] with the aim of producing 50× of data for each isolate 
[8]. The controls had to pass the following QC metrics for 
the sequence run to pass QC: no- template control must have 
<95 000 reads (equating to <1 % contamination) matching to 
a species in Kraken [8]; negative control must have its best 
match to E. coli in Kraken, have <0.4 % of reads (equating to 
<1 % contamination) in Kraken matching to another species 
[8], have no S. aureus ST identified, and have no mec gene 
identified; positive control must have its best match to S. 
aureus in Kraken, have <0.4 % (equating to <1 % contamina-
tion) of reads in Kraken matching to another species [8], be 
identified as ST22, positive for mecA, and have at least 80 % 
of the CC22 mapping reference genome covered with at least 
20× depth. Two sequence runs failed QC based on low output 
of data for the positive control (<20× depth and <80 % of the 
reference covered) and were repeated (Table S1). The positive 
control strain is available upon request.
All clinical isolates had to pass the following QC metrics: 
have their best match to S. aureus in Kraken, be positive 
for mecA/mecB/mecC, have <4 % reads (equating to <10 % 
contamination) in Kraken matching to another species [8], 
and have at least 80 % of the CC22 mapping reference genome 
covered at least 20× depth. Of the 789 isolates from 784 
patients in the study collection, 25 failed these QC metrics 
the first time due to incorrect species [n=3; Corynebacte-
rium striatum (n=1), Staphylococcus haemolyticus (n=2)]; 
contamination with a different species [n=7; S. haemolyticus 
(n=4), Staphylococcus capitis (n=1)]; no mec gene (n=4);<20× 
depth (n=10); or <80 % of the reference covered at 20× depth 
(n=5). After re- purification of the original culture to re- isolate 
MRSA, 22 of 25 isolates were successfully re- sequenced, 
leaving a total of 786 isolates that were included in the analysis 
(Table S2). Of the 25 isolates failing the initial QC metrics, 24 
were from the prospective collection and one was from the 
retrospective archives. Of the five isolates failing QC due to 
heterozygous sites, all five were from prospective collection.
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Fig. 1. CC- specific versus a single mapping reference. (a) Graph showing the relationship between pairwise SNP distances based on 
mapping to a CC22 reference and mapping to a CC- specific reference, for all isolate pairs <50 SNPs apart that belonged to STs with 
>10 isolates in the collection, based on either method. Line indicates an exact match between the two methods. (b) Graph showing the 
number of SNPs different between CC22 and CC- specific mapping based on isolate pairs belonging to CC22 (orange) or non- CC22 (blue) 
STs.
Applicability to alternative settings
To determine the applicability of CC22 mapping to alterna-
tive clinical settings, raw fastq files were downloaded from 
the European Nucleotide Archive that were submitted by 
two studies that have been described previously [11, 12]. The 
first study collection consisted of 425 MRSA isolates asso-
ciated with bloodstream infection in patients from across 
the UK between 2012–2013. Two clinical isolates failed our 
QC metrics (based on lack of mec gene detection) and were 
excluded, leaving 423 isolates for further analysis. The second 
collection consisted of 742 clinical isolates from two NHS 
hospital groups and a general district hospital in South- East 
London between 2011 and 2012. A total of 152 isolates failed 
our QC metrics for the following reasons: not being best 
matched to S. aureus in Kraken (n=8), >4 % of reads in Kraken 
matching to another species (n=80), no mec gene detected 
(n=54), or <20× depth of coverage (n=10) leaving a total of 590 
isolates for further analysis. These were mapped to the CC22 
reference and CC- specific mapping references as described 
above, with AUS0325 (accession number LT615218) used as 
the mapping reference for CC88.
RESuLTS
overview of patients and isolates
We sequenced 786 MRSA isolates from samples submitted 
to the clinical laboratory from 782 patients. The majority of 
patients had isolates submitted from Cambridge University 
Hospitals (n=485), the remainder being from patients at two 
other hospitals in the locality (hospital A and hospital B) (112 
and 44 cases, respectively) and GP surgeries (n=141). The 
majority of isolates were from multisite screens (528/786; 
67 %), with the remainder from clinical samples including 
seven isolates (1 %) grown from blood cultures taken from six 
patients. In silico MLST from the sequence data demonstrated 
that the most common STs were ST22 (n=368, 47 %), followed 
by ST45 (n=81, 10 %) and ST59 (n=62, 8 %) with a total of 66 
STs including 15 novel STs identified (Table S2). A total of 
781 isolates were mecA (99 %) with the remaining five isolates 
containing mecC.
CC-specific versus a single mapping reference
We evaluated whether a single reference could be used 
for mapping, rather than the common practice of using 
CC- specific references [11, 13]. We based the analysis on 
isolates that were assigned to STs containing more than ten 
isolates (an arbitrary cut- off) (n=655, 83 %). The single CC22 
reference used represented the dominant clonal complex in 
the collection and was ~46 000 and 53 000 SNPs from the next 
most common STs in the collection (ST59 and ST45). Fig. 1 
shows a comparison of isolates that were within 50 SNPs of 
each other using a CC22 reference alone or a CC- specific 
mapping reference (n=399 isolates). There was a positive 
association between CC- specific versus CC22 mapping, with 
a median of 0 SNPs different (range 0–19) between the two 
approaches across all 399 isolates (9597 pairs), and a median of 
three SNPs different (range 0–19) for the 602 non- CC22 pairs 
(Fig. 1). We have reported elsewhere that a SNP cut- off of 25 
SNPs robustly captures transmission events (Coll et al., under 
review). Based on binary categories of related (0–25 SNPs) 
or unrelated (>26 SNPs) for CC22 mapping, there were 44 
pairwise discords (0.46 % of the total of 9632). A single ST59 
pair was 25 SNPs apart based on CC22 mapping but 27 SNPs 
apart based on CC- specific mapping, and 43 isolate pairs were 
>25 SNPs (26–38 SNPs) apart based on CC22 mapping but 
<25 SNPs (14–24 SNPs) apart based on CC- specific mapping 
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(Fig. S1). This provides a concordance of 93.6 % for non- CC22 
isolate pairs and 99.5 % for all isolate pairs.
We repeated the analysis based on CC22 and CC- specific 
mapping in which we compared only a single randomly 
chosen genome that was <50 SNPs different for each isolate. 
This resulted in a median of 0 SNPs different (range 0–19 
SNPs) with 65 % of the comparisons (total of 399 compari-
sons) comprising CC22 isolates. There were 9 discrepancies 
(2 %), with higher numbers of SNPs called using the CC22 
mapping method. This provides a concordance of 93.6 % for 
non- CC22 isolate pairs and 98 % for all isolate pairs.
To determine whether the results were comparable with a 
different mapping reference we repeated the analysis using 
a generic CC30 reference. A total of 17 isolates (2 %) in the 
collection belonged to ST30. This demonstrated a median 
of 3 SNPs (range 0–24 SNPs) different between CC30 and 
CC- specific mapping across the isolate pairs (Fig. S2). 
Based on a 25 SNP cut- off, 1046 isolate pairs (10.8 %) were 
discrepant, providing an overall concordance of 89.2 %.
To investigate whether these findings are applicable to other 
clinical settings, we repeated the analysis using two other 
MRSA collections that have been described previously 
[11, 12], drawn from across the UK and from South- East 
London, respectively. The ST profiles of each collection are 
shown in Fig. S3. The analysis was based on isolates assigned to 
STs containing >5 isolates for the UK collection (n=362, 86 %), 
and >10 isolates for the London collection (n=500, 85 %), and 
focused on isolate genomes that were <50 SNPs different from 
another genome. When comparing CC22 and CC- specific 
mapping, there was a median of 0 SNPs (range 0–9 SNPs) 
and 0 SNPs (range 0–25 SNPs) different for all isolates and a 
median of 2 SNPs (range 0–9 SNPs) and 4 SNPs (range 0–25 
SNPs) different for non- CC22 isolates, based on the UK and 
London collections, respectively. Based on binary categories 
of related (0–25 SNPs) or unrelated (>26 SNPs), there were 37 
pairs of related isolates in the national collection (of which 
27 were ST22 pairs), with 100 % concordance between CC22 
and CC- specific mapping, and 1196 pairs of related isolates 
in the regional collection (of which 1118 were ST22), with 19 
discrepancies between CC22 and CC- specific mapping. All 19 
discrepancies in the regional collection belonged to ST8 (n=3) 
or ST36 (n=16), accounting for 21 and 36 % of related pairs 
and 0.6 and 1.1 % of all pairs in these STs, respectively. For the 
national and regional collections, respectively, this provided 
an overall concordance rate of 100 and 75.6 % for non- CC22 
isolate pairs and 100 and 98.4 % for all isolate pairs.
Defining the depth required to call a SnP
We explored the extent to which the number of called SNPs 
varied at different thresholds for the minimum depth of 
coverage required to call a base as present (as opposed to an 
unknown base call, which would not count towards the SNP 
count). This was evaluated over incremental 2× steps between 
4× (which has been used previously [5]) and 20× using data 
from 43 independent sequencing runs of the MRSA control 
after mapping to a CC22 reference. The mean SNP number 
identified decreased as the threshold required to call a base as 
present increased (Fig. 2), with 101 SNPs at 20× rising to 115 
SNPs at 4×. The SNP range across the 43 runs was highest at 
a 20× threshold for calling a base as present (37 SNPs) and 
lowest at a 4× threshold for calling a base as present (8 SNPs) 
(Table S3). There was comparable SNP calling at 4× (mean 
115, range 8 SNPs), 6× (mean 114, range 9 SNPs) and 8× 
(mean 113, range 9 SNPs) at a base, regardless of the mean 
depth across the genome (Table S3).
The number of SNPs identified in the sequences with the 
highest mean depth of coverage across the genome would 
be predicted to be the true number of SNPs, on the basis 
that these have the most data to support base- calling. This 
is supported by findings that the SNP range was smallest at 
the highest mean depth of coverage across the different base 
depth thresholds evaluated (5 SNPs at >90× mean depth of 
coverage across the genome, increasing to 37 SNPs at 30–40×). 
Based on this, thresholds of 4–8× depth at a base provided 
SNP calls across the different genome coverage depths that 
were closest to the predicted true number of SNPs (Fig. 2). 
At thresholds of both 4× and 6× for a base, the same number 
of SNPs were identified at the highest genome depth of 92× 
and at ~40× depth.
To determine how SNP calling varied depending on the 
mapping reference used, we repeated the mapping of the 
43 positive MRSA control runs, together with three study 
isolates that were ~100 SNPs from the MRSA control, to a 
CC30 reference (Fig. S4). These three study isolates were 
used to assess a similar SNP difference to the CC22 reference 
method (~100 SNPs), since the MRSA control is too distant 
(thousands of SNPs) from the CC30 reference to perform an 
accurate comparison of the methods. A similar pattern was 
observed, with the number of SNPs decreasing as the depth 
required to call a SNP increased (Fig. S4). As with the CC22 
reference, the lowest range of SNPs called occurred between 
4–8× (12–15, 11–12 and 11–12 SNPs for the three isolates, 
respectively).
Defining the limit for variation in SnPs allowed for 
the positive control
Our methodology for sequencing does not include PhiX 
[8], and instead uses a positive MRSA control (MRSA 
MPROS0386) to control for the accuracy of base calling by the 
sequencer. We first determined the limit of variability in SNPs 
permitted for this control using data that we have generated 
previously for MRSA MPROS0386 over nine independent 
sequencing runs [8]. We calculated the expected number 
of SNPs compared to the mapping reference with mobile 
elements removed. Based on a minimum cut- off of 4× to 
call a SNP, a mean of 115 SNPs and range of 113–117 SNPs 
was identified, with a standard deviation of 1.4. Allowing 2 
or 3 standard deviations from the mean resulted in cut- offs 
of 112.6–118.3 and 111.2–119.7 SNPs, rounded to 113–118 
and 111–120 SNPs, both of which were sufficient to include 
all SNP differences identified across the nine sequence runs. 
We then applied this cut- off to the 43 positive MRSA control 
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Fig. 2. Sequencing depth to call a SNP as present. Graph showing the number of SNPs identified against the HO 5096 0412 mapping 
reference with MGEs removed (y- axis) in 43 sequencing replicates of MPROS0386 with different average depths of coverage (x- axis) 
based on varying thresholds for the depth of coverage required to call a SNP as present.
sequences generated here, which resulted in 111–118 SNPs 
and 3.2 standard deviations from the mean but fell within 
the rounded cut- off for 3 standard deviations from the mean 
designated as 111–120 SNPs. We re- calculated the number of 
SNPs for the positive control based on the higher cut- offs for 
calling a SNP of 6× and 8×. This resulted in a mean of 115 and 
114 SNPs, range of 111–117 and 109–117 SNPs and standard 
deviation of 1.9 and 2.4 for 6× and 8×, respectively. Using 3 
standard deviations from the mean, this resulted in a range of 
109.1–120.3 and 106.5–120.6 SNPs (rounded to 109–120 and 
107–121 SNPs), respectively. A total of 42/43 positive control 
run results from the study resided within these bounds, with a 
range of 111–116 SNPs, the exception being a single positive 
control isolate (ID: SAU051118), which had 108 SNPs.
Defining a cut-off for the detection of mec genes
The mean depth of coverage across the mec genes (mecA 
and mecC) in the 786 isolates was 53× (range 8×–126×). 
Comparison between the depth of coverage across the entire 
mapping reference and the depth of coverage of the mec genes 
revealed a positive association, with one clear outlier (Fig. 3a). 
Low depth of coverage of the mec gene when compared to 
the depth of coverage across the mapping reference could 
indicate MRSA contamination of an MSSA isolate. Therefore, 
we aimed to determine a minimum depth at which the mec 
gene could be classified as present based on 1, 2 or 3 standard 
deviations below the mean depth across the genome (Fig. 3b). 
Based on the study dataset (which had a minimum of 27× 
depth of coverage across the mapping reference), the lowest 
cut- off at 1, 2 and 3 standard deviations from the mean was 
17.3×, 5.9× and −12.7×, respectively (Fig. 3b). Based on these 
cut- offs, a total of 21 (2.7 %), 1 (0.1 %) and 0 (0 %) of the full 
study collection, respectively, failed based on mec gene depth 
of coverage. Since at 3 standard deviations the mec gene depth 
would frequently pass as present at ~0× depth (Fig. 3b), this 
option was excluded. The single isolate failing the 2 standard 
deviations cut- off had a mecA gene depth of 8.3×, which 
was 20 % of the mapping reference depth (43×). In addition, 
the gene was split into two sections based on Ariba, one of 
1192 bp and one of 849 bp. The additional 20 isolates failing 
QC at 1 standard deviation had mec gene depths 70–76 % of 
the depth of the mapping reference depth (30–62× over mecA, 
41–81× over the mapping reference). Based on these data we 
suggest that mec genes with a depth that is at most 2 standard 
deviations below the mean depth across the mapping refer-
ence should be called as present, and those with a greater 
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deviation should be failed and investigated further in the 
laboratory. This requires calculating the depth of coverage 
across the mapping reference, the standard deviation of depth, 
and the depth of coverage across the mec gene for each new 
isolate and performing a simple calculation.
Defining a cut-off for same-species contamination
We determined a cut- off that could be used to identify same- 
species contamination based on the number of heterozygous 
sites (hetSNPs) detected when mapped to the CC22 reference 
genome. The number of heterozygous sites identified in the 
786 clinical MRSA isolates ranged from 0 to 6046 (median 5, 
Fig. 4a). Stratification by ST revealed that ST22 and related 
STs had substantially lower numbers of heterozygous sites 
compared to non- ST22s (Fig. S5a). Analysis of the chromo-
somal location of heterozygous sites within and between STs 
using three representative isolates from each of the top three 
STs revealed that the majority of hetSNPs were clustered 
together in the genome, with similar ‘hot- spot’ locations iden-
tified within STs and different ‘hot- spot’ locations between 
STs (Fig. S6). These ‘hot- spots’ could be due to homologs as 
opposed to contamination, therefore to remove these hot- 
spots we compared the number of heterozygous sites that 
were identified at differing intervals of >50 bp to >500 bp apart 
for multiple sequences of two ST22 isolates (MPROS1839 and 
MPROS2264) that had been spiked with between 0–20 % of a 
distinct ST22 isolate (MPROS0386, see Methods). In the pure 
isolates (0 % contamination), the majority of hetSNPs were 
found to be <50 bp apart (Fig. S7). Therefore, hetSNPs <50 bp 
apart were removed from the analysis. Applying this filter 
resulted in the number of hetSNPs >50 bp apart increasing 
with the proportion of contamination (Fig. S7) and reduced 
the disparity between ST22 and other STs (Fig. S5b). Iden-
tification of hetSNPs that were 50 bp apart showed that the 
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Fig. 5. A final QC flowchart for passing/failing positive (MPROS0386), negative (NCTC12241) and no template controls and clinical 
isolates during clinical MRSA sequencing. Note that 0.4 and 4 % of reads matching another species in Kraken equates to contamination 
of 1 and 10 %, respectively. If any of the controls fail any of the QC metrics, the entire sequence run will fail and require re- sequencing. If 
clinical isolates fail any of the QC metrics, that single isolate is failed and should be repeated without further analysis.
majority of isolates (781/786, 99.4 %) contained less than 30 
hetSNPs, with five outliers containing between 99 and 6056 
hetSNPs (Fig. 4a). One of these outliers was the single isolate 
that failed the 2 standard deviations cut- off for mecA gene 
depth, described above, further supporting that this sample 
was contaminated. Based on these findings, we propose that 
all isolate genomes should contain less than 30 hetSNPs each 
of which are >50 bp apart (Fig. 4b).
Final cut-offs and application in the clinical setting
The final metrics required for the controls and clinical isolates 
to pass QC are shown in the flowchart in Fig. 5. Based on 
these criteria, a total of 781/786 isolates passed all QC metrics.
DISCuSSIon
We undertook a detailed technical evaluation of almost 800 
clinical MRSA isolates to define quality metrics that support 
reproducible clinical MRSA sequencing. Our first question 
was to determine whether a single ‘generic’ mapping refer-
ence could be used to determine core genome SNPs, rather 
than using CC- specific mapping references [11, 13, 14]. This 
simplifies the informatics analysis and reduced the time for 
analysis because the initial in silico MLST followed by selec-
tion of a specific reference is not required. This technique 
has been used previously [15, 16], but its accuracy has not 
been determined. On the basis that previous studies in our 
setting demonstrated a predominance of MRSA CC22 [5] and 
further supported by a prevalence of 47 % for ST22 in this 
study, we mapped to a CC22 reference and compared this 
with a CC- specific mapping reference for all STs containing 
more than ten isolates. There was a clear association between 
the number of pairwise SNPs called by the two methods, but 
a higher number were called using the generic CC22 reference 
compared with CC- specific mapping for non- CC22 isolates. 
This is predictable based on the greater genetic variation 
between isolates assigned to different rather than the same 
CC. We further evaluated this using a pairwise SNP cut- off 
for likely transmission of 25 SNPs. This demonstrated a high 
concordance, suggesting that in this setting a generic refer-
ence is acceptable for clinical use. However, further work is 
required to determine whether this holds true in settings 
where ST22 is not the dominant ST and where STs with low 
concordance between CC22 and CC- specific mapping, such 
as ST36, have a higher prevalence. This will also be important 
to determine for cases where there is a significant shift in 
the dominant lineage over time. We found a reduction in 
prevalence of ST22 in our setting from 68 % in 2012–2013 
[5] to 47 % in this study, which could alter the expected 
concordance of the data. Methods to overcome this will need 
to be developed to future- proof the technology. In the future, 
possible solutions for this could include a scale of SNP cut- 
offs dependent upon the proportion of the mapping reference 
covered or use of a core genome shared across STs. Until 
such evidence becomes available, the use of a single mapping 
reference and SNP cut- off for transmission remains the most 
computationally simple option, with no requirement for an 
initial MLST identification step.
In this study we used a single mapper and variant caller, but 
we note that there are multiple mapper and variant caller 
combinations available which vary in their sensitivity to 
SNP detection [17] and have a range of variables that can be 
altered. Ideally in the future, a single analysis approach would 
be adopted to allow between- hospital comparison. Until such 
time, alternative mapper/variant caller combinations will 
need to be tested to verify their concordance, for which the 
data available in this manuscript can be used as a guide.
In our current pipeline, we aim for a median depth greater 
than 50× based on 21 isolates and three controls [8], which 
was achieved in 72 % of the sequences in this study. Minor 
pipetting errors and low- yield runs by the sequencer can 
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lead to lower depth, and our QC cut- off for depth is 20×. 
Previous studies evaluating the development of clinical 
MRSA sequencing have used cut- offs of 30× [18] and 60× 
[19]. However, the latter was suggested based on E. coli and 
S. typhimurium genomes and there was insufficient data to 
support this cut- off for S. aureus since there were 0 SNPs 
between the validation sample and reference at all coverage 
depths. We found that when the depth to call a SNP as 
present was increased towards the cut- off for the genome 
depth (20× in this study) the number of SNPs called fell. Our 
findings that the same number of SNPs were identified at 
the highest depth of coverage across the genome (92×) and 
at ~40× depth, for both the 4× and 6× thresholds, supports 
targeting 50× coverage across the genome and suggests 
that the requirement for at least 60× reported previously 
[19] may be too stringent. We found that defining a SNP 
as present at 4–8× resulted in the smallest range of SNPs 
identified. Based on the limit for variation in SNPs allowed 
in the positive control, one MRSA control isolate failed 
QC at 6×. When this isolate was removed, 6× resulted in 
the smallest range of SNPs (6 SNPs at 6× vs 8 SNPs at 4×) 
suggesting that a threshold of 6× is sufficient to accurately 
call a SNP.
Our clinical MRSA sequencing methodology includes a 
positive MRSA control to control for the accuracy of base 
calling by the sequencer rather than PhiX, which led us to 
define the limit of variation in SNPs allowed for the positive 
control. We allowed 3 standard deviations from the mean, 
which resulted in a SNP range of 111–120 SNPs when using 
the 4× cut- off for defining a SNP, up to 107–121 SNPs when 
using the 8× cut- off. The exact range of SNPs may vary if a 
different mapping or SNP calling methodology is utilized by 
future automated analysis pipelines, but the data provided 
here could be utilized to reproduce the expected SNPs for 
these.
Looking ahead to future practice when sequencing could 
replace phenotypic antimicrobial susceptibility testing, we 
aimed to define a robust measure for the detection of mec 
genes based on depth of coverage. Low coverage of the mec 
gene in comparison to the remainder of the genome could 
indicate low level contamination of an MSSA with MRSA, 
thereby calling a false- positive. We demonstrated that a 
cut- off of 2 standard deviations below the average coverage 
depth across the mapping reference could be used to define 
mec genes as either present or potentially absent. Our find-
ings indicate that 1 standard deviation may be too stringent, 
whilst 3 standard deviations could allow false- positives. We 
suggest that those with mec genes at coverages lower than 
the cut- off are tested further in the laboratory to confirm 
absence of mecA and exclude a mixed population.
Compared with sequencing performed for research 
purposes using highly purified bacterial stock, sequencing 
from clinical plates runs an increased risk of contamination 
in which more than one S. aureus strain is inadvertently 
sequenced, although the likelihood of mixed carriage is 
low [5]. In addition, it is possible that during laboratory 
processing, contamination from one sample to another 
could occur. This could lead to erroneously high related-
ness in the event that bases at heterozygous positions are 
excluded, which is standard practice. To address this, we 
determined a cut- off that could be used to identify same- 
species contamination based on the number of hetSNPs 
detected. We found that including all hetSNPs resulted in an 
inability to identify contamination since ST22 isolates had 
lower hetSNPs than other STs. Our 50 bp cut- off allowed 
hot- spots of hetSNPs, which appeared to be specific to STs, 
to be accounted for and resulted in five outlying isolates. 
The data in this study indicates that a cut- off of 30 hetSNPs 
>50 bp apart allows distinction between the majority of 
strains and outliers likely to be contaminated. However, 
whilst the parameters used should detect high- level (>10 %) 
contamination with a different S. aureus strain, low- level 
contamination and contamination with a genetically similar 
isolate may be missed. Parameters for detection of contami-
nation with a different species have been described by us 
[8] and others [19], but to our knowledge identification of 
same- species contamination for S. aureus for clinical use 
has not been reported.
The final metrics required for the controls and clinical isolates 
to pass QC were combined into a flowchart for ease of use. 
This study was performed by manually inputting command 
lines to run each separate bioinformatic tool, and the next step 
in implementing real- time whole- genome sequencing into 
clinical practice will be the generation of a fully automated 
analysis- pipeline. Work on this is currently underway, and we 
have recently performed a pilot study into an automated pipe-
line developed by Next Gen Diagnostics [10]. The parameters 
defined in this study can be integrated into these automated 
pipelines, ultimately resulting in rapid hands- off sequencing 
and analysis in the clinical laboratory, and to guide future 
adopters of whole- genome sequencing. In conclusion, these 
methods support reliable and reproducible clinical MRSA 
sequencing in clinical practice.
Funding information
This publication presents independent research supported by the 
Health Innovation Challenge Fund (WT098600, HICF- T5-342), a parallel 
funding partnership between the Department of Health and Wellcome 
Trust. The views expressed in this publication are those of the author(s) 
and not necessarily those of the Department of Health or Wellcome 
Trust. This project was also funded by a grant awarded to the Wellcome 
Trust Sanger Institute (098051). F.C. is funded by a Wellcome Trust Sir 
Henry Postdoctoral Fellowship (201344/Z/16/Z).
Conflicts of interest
S.J.P., J.P. and F.C. are consultants to Next Gen Diagnostics, and S.J.P. is 
a consultant to Specific Technologies. E.B. is an employee of Next Gen 
Diagnostics. The other authors have no conflicts of interest.
Ethical statement
This was a laboratory- based study in which all samples were collected 
as part of routine clinical care, and patients from whom bacte-
rial samples were collected were not approached or consented for 
participation. Bacterial isolates and cases were assigned a unique 
anonymized strain identification number. This was approved by the 
National Research Ethics Service (ref: 11/EE/0499) and the Cambridge 
University Hospitals NHS Foundation Trust Research and Development 
Department (ref: A092428).
10
Raven et al., Microbial Genomics 2020
Five reasons to publish your next article with a microbiology Society journal
1.  The Microbiology Society is a not-for-profit organization.
2.  We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3.   Our journals have a global readership with subscriptions held in research institutions around  
the world.
4.  80% of our authors rate our submission process as ‘excellent’ or ‘very good’.
5.  Your article will be published on an interactive journal platform with advanced metrics.
Find out more and submit your article at microbiologyresearch.org.
Data Bibliography
1. Toleman, M.S., Reuter, S., Jamrozy, D., Wilson, H.J., Blane, B., Harrison, 
E.M., Coll, F., Hope, R.J., Kearns, A., Parkhill, J., Peacock, S.J., Torok, M.E. 
European Nucleotide Archive, ERP005128 (2019).
2. Tosas Auguet, O., Stabler, R.A., Betley, J., Preston, M.D., Dhaliwal, 
M., Gaunt, M., Ioannou, A., Desai, N., Karadag, T., Batra, R., Otter, J.A., 
Marbach, H., Clark, T.G., Edgeworth, J.D. European Nucleotide Archive, 
PRJEB11177 (2016).
References
 1. Harris SR, Cartwright EJP, Török ME, Holden MTG, Brown NM 
et  al. Whole- genome sequencing for analysis of an outbreak of 
meticillin- resistant Staphylococcus aureus: a descriptive study. 
Lancet Infect Dis 2013;13:130–136.
 2. Köser CU, Holden MTG, Ellington MJ, Cartwright EJP, 
Brown NM et al. Rapid whole- genome sequencing for investigation 
of a neonatal MRSA outbreak. N Engl J Med 2012;366:2267–2275.
 3. Eyre DW, Golubchik T, Gordon NC, Bowden R, Piazza P et al. A pilot 
study of rapid benchtop sequencing of Staphylococcus aureus and 
Clostridium difficile for outbreak detection and surveillance. BMJ 
Open 2012;2:e001124.
 4. Tong SYC, Holden MTG, Nickerson EK, Cooper BS, Köser CU et al. 
Genome sequencing defines phylogeny and spread of methicillin- 
resistant Staphylococcus aureus in a high transmission setting. 
Genome Res 2015;25:111–118.
 5. Coll F, Harrison EM, Toleman MS, Reuter S, Raven KE et al. Longi-
tudinal genomic surveillance of MRSA in the UK reveals trans-
mission patterns in hospitals and the community. Sci Transl Med 
2017;9:eaaak9745.
 6. Török ME, Harris SR, Cartwright EJP, Raven KE, Brown NM et al. 
Zero tolerance for healthcare- associated MRSA bacteraemia: is it 
realistic? J Antimicrob Chemother 2014;69:2238–2245.
 7. Peacock SJ, Parkhill J, Brown NM. Changing the paradigm for 
hospital outbreak detection by leading with genomic surveillance 
of nosocomial pathogens. Microbiology 2018;164:1213–1219.
 8. Raven KE, Blane B, Leek D, Churcher C, Kokko- Gonzales P et al. 
Methodology for whole genome sequencing of MRSA in a routine 
hospital microbiology laboratory. J Clin Microbiol 2019.
 9. Blane B, Raven KE, Leek D, Brown N, Parkhill J et  al. Rapid 
sequencing of MRSA direct from clinical plates in a routine micro-
biology laboratory. J Antimicrob Chemother 2019;74:2153–2156.
 10. Brown NM, Blane B, Raven KE, Kumar N, Leek D et al. Pilot evalu-
ation of a fully automated bioinformatics system for the analysis 
of MRSA genomes and detection of outbreaks. J Clin Microbiol 
2019;57.
 11. Toleman MS, Reuter S, Jamrozy D, Wilson HJ, Blane B et  al. 
Prospective genomic surveillance of methicillin- resistant Staphy-
lococcus aureus (MRSA) associated with bloodstream infection, 
England, 1 October 2012 to 30 September 2013. Euro Surveill 
2019;24:1800215.
 12. Tosas Auguet O, Stabler RA, Betley J, Preston MD, Dhaliwal M et al. 
Frequent undetected ward- based methicillin- resistant Staphy-
lococcus aureus transmission linked to patient sharing between 
hospitals. Clin Infect Dis 2018;66:840–848.
 13. Reuter S, Török ME, Holden MTG, Reynolds R, Raven KE et  al. 
Building a genomic framework for prospective MRSA surveillance 
in the United Kingdom and the Republic of Ireland. Genome Res 
2016;26:263–270.
 14. Hsu L- Y, Harris SR, Chlebowicz MA, Lindsay JA, Koh T- H et  al. 
Evolutionary dynamics of methicillin- resistant Staphylococcus 
aureus within a healthcare system. Genome Biol 2015;16:81.
 15. Tong SYC, Holden MTG, Nickerson EK, Cooper BS, Köser CU et al. 
Genome sequencing defines phylogeny and spread of methicillin- 
resistant Staphylococcus aureus in a high transmission setting. 
Genome Res 2015;25:111–118.
 16. Price JR, Cole K, Bexley A, Kostiou V, Eyre DW et  al. Transmis-
sion of Staphylococcus aureus between health- care workers, the 
environment, and patients in an intensive care unit: a longitudinal 
cohort study based on whole- genome sequencing. Lancet Infect Dis 
2017;17:207–214.
 17. Bush SJ, Foster D, Eyre DW, Clark EL, De Maio N et al. Genomic 
diversity affects the accuracy of bacterial SNP calling pipelines. 
bioRxiv.
 18.  Durand G, Javerliat F, Bes M, Veyrieras J- B, Guigon G et al. Routine 
whole- genome sequencing for outbreak investigations of Staphy-
lococcus aureus in a national reference centre. Front Microbiol 
2018;9:511.
 19. Kozyreva VK, Truong C- L, Greninger AL, Crandall J, Mukhopad-
hyay R et  al. Validation and implementation of clinical labora-
tory improvements act- compliant whole- genome sequencing 
in the public health microbiology laboratory. J Clin Microbiol 
2017;55:2502–2520.
